With the objective of enlarging its production capacity, examining new manufacturing practices and optimizing its management and organization, SIPHAT pursues a carefully studied investment policy. Modern and sophisticated equipments, optimal scientific manufacturing and management techniques and strengthened relations with its partners, all these factors breathe new life into the company.

Read More

SIPHAT investments since 2005

• Rehabilitation of the ointments and suppositories production units.
• Rehabilitation of the drinkable ampoules producing.
• Rehabilitation of storage areas, sampling and weighing rooms.
• Installation and start up of the production line of perfusable solutions in bags “Clear Flex”.Construction of 3 warehouses of 3000 m².
• Acquisition of various production equipments (mixing, granulating and drying line; coating machine; blistering machine; rotary tabletting machine; filling line for perfusable solutions in bottles; bottle sterilizer; material for preparing  perfusable solutions and blister label bander; steam boiler)
• Implementation of an integrated management software package “ERP”.
• Rehabilitation of the dry forms production unit.
• Arrangements of premises intended for the company Pierre Fabre.

Equity portfolio

SIPHAT is the only firm of this sector that holds shares in other pharmaceutical industries :

• Saiph : 15,97%
• Pfizer-Tunisie : 30%
• Pierre Fabre Production Médicaments-Tunisie : 35%
• Technopole de Sidi Thabet : 5%